NORP – Talk Bio

Curapath and Cristal Therapeutics Sign Co-Exclusive License of CliCr Bioconjugation Platform

2 weeks ago talkbio0Tagged Bioconjugation Platform, CDMO, CliCr, co-exclusive license, Cristal Therapeutics, Curapath, Drug Delivery Systems, nucleic acid delivery

Curapath; Cristal Therapeutics; CliCr Bioconjugation Platform; co-exclusive license; nucleic acid delivery; CDMO; drug delivery

US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study

3 weeks ago talkbio0Tagged Clinical Trials, drug-resistant TB, linezolid, Phase 2 clinical trial, pretomanid, sorfequiline, SPaL, TB Alliance, Treatment Protocols, Tuberculosis, U.S., ultra-short regimen

tuberculosis; TB Alliance; Phase 2 clinical trial; sorfequiline; SPaL regimen; pretomanid; linezolid; drug-resistant TB; ultra-short regimen; US support; clinical trial results

Eli Lilly Signs Up to $2.6 Billion Deal with South Korean Biotech for RNA Medicine Delivery

3 weeks ago talkbio0Tagged cardiometabolic, Deal Value, eli lilly, LEAD platform, Metabolic Diseases, News [Publication Type], Pharma, RNAi medicines, SanegeneBio, South Korean biotech, strategic partnership

Eli Lilly; SanegeneBio; South Korean biotech; RNAi medicines; metabolic diseases; LEAD platform; strategic partnership; cardiometabolic; deal value; pharma news

Nuvalent Shares Positive Phase 1/2 ALK Inhibitor Data Rivaling Pfizer’s Lorbrena in Lung Cancer

3 weeks ago talkbio0Tagged ALK Inhibitor, ALKOVE-1 trial, Clinical Trials, CNS activity, Frequency of Responses, Lorbrena, lorlatinib, neladalkib, Non-Small Cell Lung Carcinoma, Nuvalent, Phase 1/2 data, United States Food and Drug Administration

Nuvalent; neladalkib; ALK inhibitor; ALKOVE-1 trial; Phase 1/2 data; non-small cell lung cancer (NSCLC); lorlatinib; Lorbrena; FDA; clinical trial; objective response rate; CNS activity

Zimmer Biomet Receives U.S. FDA Clearance for Enhanced ROSA Knee Robotic Technology

3 weeks ago talkbio0Tagged Clearance, OptimiZe technology, Personalized, robotic knee replacement, ROSA Knee, surgical planning, United States Food and Drug Administration, Zimmer Biomet

Zimmer Biomet; FDA clearance; ROSA Knee; OptimiZe technology; robotic knee replacement; personalized surgical planning

Mikael Dolsten Withdraws Candidacy for Novo Nordisk Board; Bavarian Nordic Chairman Resigns

4 weeks ago talkbio0Tagged Bavarian Nordic, board of directors, board shake-up, chairman resignation, Danish pharma, Mikael Dolsten, Nordisk, personal reasons, Withdraw (activity)

Mikael Dolsten; Novo Nordisk; board of directors; withdrawal; personal reasons; Novo Nordisk Foundation; board shake-up; Danish pharma; Bavarian Nordic; chairman resignation

Santen Announces Completion of Share Buyback

1 month ago talkbio0Tagged buyback, Dosage Forms, equity buyback, Japanese language, Occupational activity of managing finances, repurchase, Santen, shareholder value

Santen Pharmaceutical; share buyback; repurchase; equity buyback; shareholder value; Japanese pharmaceuticals; financial management

Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry

1 month ago talkbio0Tagged Amsterdam facility, Awards, cell analysis, Collaboration, Cytek Biosciences, European (ethnic group), expansion, Flow Cytometry, FSP, Instrument - device, ISAC, Research Projects, R-Series, Spectrum Profiling

Cytek Biosciences; flow cytometry; access expansion; ISAC collaboration; instrument awards; research grants; Full Spectrum Profiling (FSP); European expansion; Amsterdam facility; cell analysis

FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal

1 month ago talkbio0Tagged Acute leukemia, Antibody-Drug Conjugates, Approved, black-box warning, Chromosomal translocation, differentiation syndrome, KMT2A gene, Leukemia, Myelocytic, Acute, Menin Inhibitor, oncology drug approval, Revuforj, revumenib, SmithKline Beecham, Syndax, United States Food and Drug Administration

Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval

Roche Inks $80M Upfront Deal for Hansoh’s Cancer ADC HS-20110

2 months ago talkbio0Tagged CDH17 protein, human, Colorectal Carcinoma, Hansoh Pharmaceutical, HS-20110, milestone payments, Roche (company), royalties, Solid Neoplasm, therapeutic autologous dendritic cells, upfront payment

Roche; Hansoh Pharmaceutical; ADC; HS-20110; CDH17; colorectal cancer; solid tumors; licensing deal; upfront payment; milestone payments; royalties